Cargando…

Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction

AIMS: Heart failure (HF) is a proinflammatory disease often associated with the onset of iron deficiency (ID). ID alters mitochondrial function, reducing the generation of cellular energy in skeletal muscle and cardiomyocytes. This study aimed to analyse the response of patients with HF to intraveno...

Descripción completa

Detalles Bibliográficos
Autores principales:	López‐Vilella, Raquel, Lozano‐Edo, Silvia, Arenas Martín, Patricia, Jover‐Pastor, Pablo, Ezzitouny, Meryem, Sorolla Romero, José, Calvo Asensio, María, Martínez‐Solé, Julia, Guerrero Cervera, Borja, Sánchez Martínez, José Carlos, Donoso Trenado, Víctor, Sánchez‐Lázaro, Ignacio, Martinez Dolz, Luis, Almenar Bonet, Luis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788053/ https://www.ncbi.nlm.nih.gov/pubmed/34964300 http://dx.doi.org/10.1002/ehf2.13753

Ejemplares similares

Is the Benefit of Treating Iron Deficiency Greater in Acute Heart Failure with Renal Dysfunction?
por: López-Vilella, Raquel, et al.
Publicado: (2023)

Why Iron Deficiency in Acute Heart Failure Should Be Treated: A Real-World Clinical Practice Study
por: López-Vilella, Raquel, et al.
Publicado: (2022)

COVID-19 and Heart Transplantation. Initial Experience in a Tertiary Hospital
por: López-Vilella, Raquel, et al.
Publicado: (2021)

COVID-19 Infection in Heart Transplants in Pre- and Postvaccination Periods
por: Donoso Trenado, Víctor, et al.
Publicado: (2022)

Therapeutic approach in heart failure with poor diuretic response: peripheral ultrafiltration vs. conventional treatment
por: López‐Vilella, Raquel, et al.
Publicado: (2023)

Value of SERCA2a as a Biomarker for the Identification of Patients with Heart Failure Requiring Circulatory Support
por: Ezzitouny, Meryem, et al.
Publicado: (2021)

The Female Sex Confers Different Prognosis in Heart Failure: Same Mortality but More Readmissions
por: López-Vilella, Raquel, et al.
Publicado: (2021)

Cardiac Allograft Rejection Induces Changes in Nucleocytoplasmic Transport: RANGAP1 as a Potential Non-Invasive Biomarker
por: Lozano-Edo, Silvia, et al.
Publicado: (2022)

Epidemiological Study of Tricuspid Regurgitation After Cardiac Transplantation. Does it Influence Survival?
por: López-Vilella, Raquel, et al.
Publicado: (2022)

Effectiveness and safety of ferric carboxymaltose therapy in peritoneal dialysis patients: an observational study
por: Portolés-Pérez, Jose, et al.
Publicado: (2019)

Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia
por: Calleja, José Luis, et al.
Publicado: (2015)

Intravenous ferric carboxymaltose for anaemia in pregnancy
por: Froessler, Bernd, et al.
Publicado: (2014)

Hypophosphatemia in children treated with ferric carboxymaltose
por: Posod, Anna, et al.
Publicado: (2020)

Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia
por: Friedrisch, João Ricardo, et al.
Publicado: (2015)

Ferric Carboxymaltose as Treatment in Women with Iron-Deficiency Anemia
por: Seid, Melvin H., et al.
Publicado: (2017)

Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose
por: Fang, Wendy, et al.
Publicado: (2019)

Short‐term changes in left and right systolic function following ferric carboxymaltose: a substudy of the Myocardial‐IRON trial
por: Santas, Enrique, et al.
Publicado: (2020)

Intravenous ferric carboxymaltose for the treatment of iron deficiency anaemia – reply
por: Cancado, Rodolfo Delfini, et al.
Publicado: (2020)

High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment
por: Boots, Johannes M. M., et al.
Publicado: (2022)

Intravenous ferric carboxymaltose and ferric derisomaltose alter the intestinal microbiome in female iron-deficient anemic mice
por: Rieg, Timo, et al.
Publicado: (2023)

Cardiovascular, liver, and renal toxicity associated with an intravenous ferric carboxymaltose similar versus the originator compound
por: Toblli, Jorge E, et al.
Publicado: (2017)

Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia
por: Steinmetz, T., et al.
Publicado: (2013)

Ferric carboxymaltose: A revolution in the treatment of postpartum anemia in Indian women
por: Rathod, Setu, et al.
Publicado: (2015)

Clinical experience with ferric carboxymaltose in the management of anemia in acute gastrointestinal bleeding
por: Ballester-Clau, Raquel, et al.
Publicado: (2019)

Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing
por: Diebold, Matthias, et al.
Publicado: (2019)

Fatal anaphylactic reaction due to ferric carboxymaltose: A case report
por: Arıcı, Aylin Mualla, et al.
Publicado: (2020)

Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia: Letter to Editor
por: Kanshaiym, Sakiyeva, et al.
Publicado: (2020)

Efficacy and Safety of Treatment With Ferric Carboxymaltose in Patients With Cirrhosis and Gastrointestinal Bleeding
por: Ballester-Clau, Raquel, et al.
Publicado: (2020)

Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose
por: Schaefer, Benedikt, et al.
Publicado: (2021)

Efficacy of ferric carboxymaltose in iron deficiency anemia patients scheduled for pancreaticoduodenectomy
por: Park, Jangho, et al.
Publicado: (2023)

Retrospective Case Reports of Anemic Pregnant Women Receiving Intravenous Ferric Carboxymaltose: Experience from a Tertiary Hospital in Spain
por: Aporta Rodriguez, Rafael, et al.
Publicado: (2016)

Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: reduction of erythropoietin dose in 4 years of follow-up
por: Lacquaniti, Antonio, et al.
Publicado: (2020)

Repeated CMV Infection in a Heart Transplantation Patient
por: Melero-Ferrer, Josep, et al.
Publicado: (2012)

Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial
por: Howaldt, Stefanie, et al.
Publicado: (2021)

The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study
por: Ponikowski, Piotr, et al.
Publicado: (2015)

Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose
por: Toblli, Jorge Eduardo, et al.
Publicado: (2014)

Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy
por: Froessler, Bernd, et al.
Publicado: (2018)

The Effect of Intraoperative Ferric Carboxymaltose in Joint Arthroplasty Patients: A Randomized Trial
por: Park, Hee-Sun, et al.
Publicado: (2019)

MON-344 Uncommon Etiology of Hypophosphatemia and Secondary Hyperparathyroidism: Ferric Carboxymaltose Infusion
por: Sever, Sakine
Publicado: (2020)

Severe Hypophosphatemia Following Ferric Carboxymaltose in a Patient With Inflammatory Bowel Disease
por: Ali, Abuobeida, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k37veum70ujiqbv8e489f8q31c